A REIT With Great V...
Health Care: Drugs
Theravance Inc. (THRX: NASDAQ)
$36.21 -1.31 | -3.49%
05/22/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 135.76M | 24.51M | 24.22M | 24.37M |
| Cost of Sales | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Operating Profit | 135.76M | 24.51M | 24.22M | 24.37M |
| Selling, General, and Administrative Expenses | 30.86M | 30.68M | 27.48M | 27.07M |
| Research & Development | 117.90M | 103.57M | 75.07M | 77.52M |
| Operating Income before D & A (EBITDA) | -13.00M | -109.74M | -78.32M | -80.22M |
| Depreciation & Amortization | 7.33M | 7.58M | 6.34M | 5.54M |
| Interest Income | 460.00K | 415.00K | 505.00K | 2.11M |
| Other Income - Net | 0.00 | 0.00 | 0.00 | 0.00 |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -19.86M | -116.90M | -84.15M | -84.79M |
| Interest Expense | 6.00M | 6.02M | 6.04M | 6.05M |
| Pre-Tax Income | -25.87M | -122.93M | -90.20M | -90.84M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -18.54M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -18.54M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -18.54M | -115.34M | -83.86M | -85.30M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-18.54M | 0.00 | 0.00 | 1.14M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -18.54M | 0.00 | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.20 | -1.41 | -1.16 | -1.35 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.20 | -1.41 | -1.16 | -1.35 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.20 | -1.41 | -1.16 | -1.35 |
| Basic Normalized Net Income/Share | -0.20 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.20 | -1.41 | -1.16 | -1.35 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.20 | -1.41 | -1.16 | -1.35 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.20 | -1.41 | -1.16 | -1.35 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.20 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with THRX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorEarnings Short Squeeze Play...
- ProSeth Klarman - Baupost Group
- ContributorStocks With Big Insider Buy...
- ContributorStocks With Big Insider Buy...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Usernew
Latest THRX Headlines from TheStreet
- Stocks Finish Flat as Earnings Wind Down 05.13.13 | 11:05 am
- Stock Futures Lower Ahead of Retail Sales 05.13.13 | 06:05 am
- 4 Stocks Spiking on Big Volume 05.10.13 | 03:05 pm
- Buffett's Long-Term, High-Dividend Plays 05.04.13 | 03:05 am
- Theravance Inc. (THRX): Today's Featured Health Care Laggard 04.19.13 | 05:04 pm
- 3 Stocks Pushing The Drugs Industry Higher 04.15.13 | 01:04 pm
- 5 Stocks Poised to Pop on Bullish Earnings 02.11.13 | 12:02 pm
- Insiders Trading THRX KSS TUES ELGX 11.06.12 | 10:11 am
- Theravance And Merck Sign Cardiovascular Disease Collaboration 10.16.12 | 08:10 am
- Theravance And Alfa Wassermann Enter Into Agreement To Develop And Commercialize Velusetrag For Gastroparesis 10.02.12 | 04:10 pm
Press Releases for THRX
- BREOâ¿¢ ELLIPTAâ¿¢ Gains US Approval For The Treatment Of COPD - PR Newswire 05.10.13 | 04:05 pm
- FDA Advisory Committee Recommends Approval Of BREOâ¿¢ ELLIPTAâ¿¢ For The Treatment Of COPD - PR Newswire 04.17.13 | 05:04 pm
Partner Headlines for THRX
- Morning Market Movers - Benzinga 04.15.13 | 09:04 am
- Pipeline Progress at Theravance - Analyst Blog - Zacks 12.05.12 | 09:12 am
- Glaxo Invests in Nigeria - Analyst Blog - Zacks 11.28.12 | 09:11 am
- For NovaBay, Simplicity Is The Father Of Invention - Seeking Alpha 11.12.12 | 09:11 am
- Loss at THRX Narrower Than Expected - Analyst Blog - Zacks 10.31.12 | 09:10 am
- Glaxo Aims to Expand Synflorix Label - Analyst Blog - NASDAQ 09.19.12 | 03:09 pm
- Glaxo Increases Stake in RGDX - Analyst Blog - NASDAQ 09.18.12 | 09:09 pm
- 5 Pharmaceutical Companies With EMA Catalysts During The Next 3 - 12 Months - Part II - Seeking Alpha 09.02.12 | 08:09 am
- Pipeline Advances at Glaxo/THRX - Analyst Blog - NASDAQ 08.27.12 | 08:08 pm
- Weekly CFO Sells Highlight: SWN, BECN, NSIT, HOLX, QLTI, THRX - GuruFocus 08.13.12 | 08:08 pm
